Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2023

27-09-2023 | NSCLC | ASO Author Reflections

ASO Author Reflections: Upfront Surgery Followed by Adjuvant Therapy: An Option for IIIA-N2 Non-small Cell Lung Cancer

Authors: Fangqiu Fu, MD, Yang Zhang, MD, Haiquan Chen, MD, PhD

Published in: Annals of Surgical Oncology | Issue 13/2023

Login to get access

Excerpt

Stage IIIA-N2 non-small cell lung cancer (NSCLC) has been categorized as a locally advanced condition. Despite numerous attempts to pinpoint the most effective treatment modalities,1,2 a consensus regarding the optimal approach for managing stage IIIA-N2 NSCLC remains elusive. Induction therapy is the most acceptable approach for patients with IIIA-N2 NSCLC, and surgery may be considered for those who have responded well to initial treatment.3,4 However, there is limited evidence concerning the role of upfront surgery in treating stage IIIA-N2 NSCLC. …
Literature
1.
Pless M, Stupp R, Ris HB, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet. 2015;386(9998):1049–56.CrossRefPubMed
2.
van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99(6):442–50.CrossRefPubMed
3.
Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(5):497–530.CrossRefPubMed
4.
Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):41–421.
5.
Metadata
Title
ASO Author Reflections: Upfront Surgery Followed by Adjuvant Therapy: An Option for IIIA-N2 Non-small Cell Lung Cancer
Authors
Fangqiu Fu, MD
Yang Zhang, MD
Haiquan Chen, MD, PhD
Publication date
27-09-2023
Publisher
Springer International Publishing
Keywords
NSCLC
NSCLC
Published in
Annals of Surgical Oncology / Issue 13/2023
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-023-14265-x

Other articles of this Issue 13/2023

Annals of Surgical Oncology 13/2023 Go to the issue

ASO Author Reflections

ASO Author Reflections: Association of Race/Ethnicity, Persistent Poverty, and Opioid Access Among Patients with Gastrointestinal Cancer Near the End of Life

Translational Research

Transferrin Receptor is Associated with Sensitivity to Ferroptosis Inducers in Hepatocellular Carcinoma

Breast Oncology

Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients

ASO Visual Abstract

ASO Visual Abstract: Growing Deficit in New Cancer Diagnoses 2 Years into the COVID-19 Pandemic—A National Multicenter Study

ASO Visual Abstract

ASO Visual Abstract: Shaving Papillary Thyroid Carcinoma Involving Functioning Recurrent Laryngeal Nerve—Safety of Incomplete Tumor Resection and Nerve Sparing

Thoracic Oncology

Long-Term Outcomes of Selected Patients with IIIA–N2 Non-small Cell Lung Cancer Receiving Upfront Surgical Resection